 
                A Molecular Glue Degrader to Control CRISPR with Drs. Krishanu Saha and Namita Khajanchi
Échec de l'ajout au panier.
  
      
      
        
                    
 
  
                        
                
 
  
Veuillez réessayer plus tard
            
                    
                
      
  
            
            
        
Échec de l'ajout à la liste d'envies.
  
      
      
        
                    
 
  
                        
                
 
  
Veuillez réessayer plus tard
            
                    
                
      
  
            
            
        
Échec de la suppression de la liste d’envies.
  
      
      
        
                    
 
  
                        
                
 
  
Veuillez réessayer plus tard
            
                    
                
      
  
            
            
        
Échec du suivi du balado
Ne plus suivre le balado a échoué
- 
    
        
 
	
Narrateur(s):
- 
    
        
 
	
Auteur(s):
À propos de cet audio
Join Dr. Paloma Giangrande, Editor-in-Chief of Molecular Therapy Nucleic Acids, as she discusses a recently published MTNA article, Controlling CRISPR-Cas9 genome editing in human cells using a molecular glue degrader, with its authors Drs. Krishanu Saha and Namita Khajanchi (UW-Madison).
If you enjoy this episode, check out our hybrid event this fall that will allow you to engage with pioneering researchers in gene editing! Breakthroughs in Targeted In Vivo Gene Editing will be held in San Diego and virtually November 20-21, 2025.
Music: 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. www.scottbuckley.com.au
Show your support for ASGCT!: https://asgct.org/membership/donate
See omnystudio.com/listener for privacy information.
                        
 
  
Pas encore de commentaire
                 
            
         
    
                                                
                                            
                                        
                                    
                            
                            
                        
                    